Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
2026-02-17 15:58:22 ET
On February 17, 2026, Rock Springs Capital Management LP disclosed in an SEC filing that it sold 159,379 shares of Agios Pharmaceuticals (NASDAQ:AGIO) in the fourth quarter, an estimated $5.59 million transaction based on quarterly average pricing.
According to its SEC filing dated February 17, 2026, Rock Springs Capital Management sold 159,379 shares of Agios Pharmaceuticals in the fourth quarter. The estimated transaction value was $5.59 million, based on the average closing price for the quarter. The fund’s quarter-end position in Agios was valued at $21.75 million, down $16.72 million from the prior period, a figure reflecting both trading and market price changes.
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of therapies for rare genetic diseases in the field of cellular metabolism. With a focused pipeline and a marketed product addressing hemolytic anemias, Agios leverages scientific expertise to address unmet medical needs. The company’s strategy centers on advancing innovative treatments for underserved patient populations, supporting its competitive position within the biotechnology sector.
NASDAQ: AGIO
AGIO Trading
3.97% G/L:
$28.005 Last:
208,618 Volume:
$27.53 Open:
